dc.contributor.author | Karakuş, Volkan | |
dc.contributor.author | Maral, Senem | |
dc.contributor.author | Kaya, Egemen | |
dc.contributor.author | Gemici, Aliihsan | |
dc.contributor.author | Dere, Yelda | |
dc.contributor.author | Sevindik, Ömür Gökmen | |
dc.date.accessioned | 2022-10-31T09:36:16Z | |
dc.date.available | 2022-10-31T09:36:16Z | |
dc.date.issued | 2022 | en_US |
dc.identifier.citation | Karakuş, V., Maral, S., Kaya, E., Gemici, A., Dere, Y. ve Sevindik, Ö. G. (2022). Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data. Northern Clinics of Istanbul, 9(4), 331-336. https://doi.org/10.14744/nci.2021.42800 | en_US |
dc.identifier.issn | 2148-4902 | |
dc.identifier.issn | 2536-4553 | |
dc.identifier.uri | https://doi.org/10.14744/nci.2021.42800 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/9897 | |
dc.description.abstract | OBJECTIVE: Acute myeloid leukemia (AML) is a hematological malignancy that frequently affects elderly population. With introducing the hypomethylating agents (HMAs) in elderly AML treatment, survival rates and quality of life have improved. However, long-term management in elderly and frail patients is still a challenge. In the present study, we aimed to determine whether HMA maintenance therapy is required until disease progression in frail and elderly AML patients by examining with a real-life data.METHODS: In a multicenter study, we analyzed non-promyelocytic elderly AML patients who were treated with first-line azacitidine or decitabine monotherapy in two different groups, retrospectively. While patients were treated with HMA until progression in the maintenance group, 6+3 cycles of azacitidine or decitabine were administered as a standard care of elderly AML patients in the non-maintenance group. Survival outcomes were compared between the groups.RESULTS: HMA therapy was maintained until progression in 20 patients, and HMA therapy was terminated after 6+3 cycles in 21 patients. Patients received a median of 6 (1-14) HMA cycles during follow-up time. The median 7.5 months of overall survival were observed (2-17 months) in maintenance and 3 months (1-13 months) in non-maintenance groups (p=0.001).CONCLUSION: Despite long-term exposure to HMA may appear as a risk factor for complications and toxicities in elderly and frail AML patients, the maintenance of therapy until disease progression provides a significant survival advantage. Therefore, we suggest that HMA therapy should continue until disease progression regardless the sort of HMA. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Kare Publishing | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Acute Myeloid Leukemia | en_US |
dc.subject | Azacitidine | en_US |
dc.subject | Decitabine | en_US |
dc.subject | Hypomethylating Agents | en_US |
dc.title | Survival outcomes of hypomethylating agents maintenance therapy in new diagnosed AML patients: Real experience data | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Northern Clinics of Istanbul | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0002-3385-8359 | en_US |
dc.authorid | 0000-0001-9636-4113 | en_US |
dc.identifier.volume | 9 | en_US |
dc.identifier.issue | 4 | en_US |
dc.identifier.startpage | 331 | en_US |
dc.identifier.endpage | 336 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.14744/nci.2021.42800 | en_US |
dc.institutionauthor | Gemici, Aliihsan | |
dc.institutionauthor | Sevindik, Ömür Gökmen | |
dc.identifier.wos | 000864526600007 | en_US |
dc.identifier.scopus | 2-s2.0-85164768023 | en_US |
dc.identifier.trdizinid | 1130076 | en_US |
dc.identifier.pmid | 36276561 | en_US |